Expression level of serum HBV RNA in HBeAg-positive chronic hepatitis B patients at different periods and its value of measurement

Chengkang WANG; Shourong LIU

doi:10.3969/j.issn.1001-5256.2021.12.014

Volume 37 Issue 12

Dec. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(12): 2798-2801

PDF( 1906 KB)

Expression level of serum HBV RNA in HBeAg-positive chronic hepatitis B patients at different periods and its value of measurement

DOI: 10.3969/j.issn.1001-5256.2021.12.014

Chengkang WANG¹,
Shourong LIU^{2
,
,}

1.
Department of Infectious Diseases, The Fourth Affiliated Hospital ZheJiang University School of Medicine, YiWu, ZheJiang 322000, China
2.
Department of Hepatology, Hangzhou Xixi Hospital, Hangzhou 310023, China

Research funding:

Hangzhou Science and Technology Bureau Plan Project (20191203B116)

Received Date: 2021-04-21
Accepted Date: 2021-05-10
Published Date: 2021-12-20

Abstract

Abstract

Objective To investigate the expression level and potential clinical value of serum HBV RNA in HBeAg-positive chronic hepatitis B (CHB) patients at different periods. Methods A total of 61 CHB patients who attended the outpatient and inpatient services of Department of Hepatology, Hangzhou Xixi Hospital, from August 2019 to December 2020 were enrolled, and according to the antiviral therapy for HBeAg-positive CHB patients, they can be divided into group A with untreated HBeAg-positive CHB (HBeAg+ and HBV DNA+) patients, group B with treatment-experienced patients before HBeAg seroconversion (HBeAg+ and HBV DNA-), and group C with treatment-experienced patients after HBeAg seroconversion (HBeAg- and HBV DNA-). Peripheral blood HBV RNA load was measured at different periods, and its correlation with HBsAg and HBV DNA was analyzed. The t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between groups; a Pearson or Spearman correlation analysis was used to describe the correlation between two variables. Results The positive rates of HBV RNA in these three groups were 100% (22/22), 88.2% (15/17), and 22.7% (6/22), respectively. In group A, HBV RNA was positively correlated with HBsAg and HBV DNA (r=0.612 and 0.922, both P < 0.01), while in groups B and C, there was no correlation between HBV RNA and HBsAg. Group B had significantly higher levels of HBV RNA and HBsAg than group C (Z=-4.44 and -2.41, both P < 0.05). The HBV DNA-positive group had a significantly higher level of HBV RNA than the HBV DNA-negative group (Z=-6.16, P < 0.01). Conclusion After HBV DNA clearance achieved by antiviral therapy with nucleos(t)ide analogues in CHB patients, serum HBV RNA can still be detected in some of these patients. Since HBV RNA only comes from cccDNA in the liver, it can better reflect viral replication activity in the liver than HBV DNA and thus has a certain clinical value in the management of CHB patients.
- Hepatitis B, Chronic,
- Hepatitis B virus,
- RNA, Viral,
- DNA, Viral,
- Hepatitis B e Antigens

FullText(HTML)

References(12)

References

[1]	TANG L, COVERT E, WILSON E, et al. Chronic hepatitis B infection: A review[J]. JAMA, 2018, 319(17): 1802-1813. DOI: 10.1001/jama.2018.3795.
[2]	LIU J, LIANG W, JING W, et al. Countdown to 2030: Eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97(3): 230-238. DOI: 10.2471/BLT.18.219469.
[3]	CUI FQ. Achievements in prevention and control of viral hepatitis since the founding of the people's Republic of China[J]. Int J Virol, 2019, 26(5): 289-292. DOI: 10.3760/cma.j.issn.1673-4092.2019.05.001. 崔富强. 中国建国以来病毒性肝炎的防控成就[J]. 国际病毒学杂志, 2019, 26(5): 289-292. DOI: 10.3760/cma.j.issn.1673-4092.2019.05.001.
[4]	NASSAL M. HBV cccDNA: Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B[J]. Gut, 2015, 64(12): 1972-1984. DOI: 10.1136/gutjnl-2015-309809.
[5]	KUMAR R, PÉREZ-DEL-PULGAR S, TESTONI B, et al. Clinical relevance of the study of hepatitis B virus covalently closed circular DNA[J]. Liver Int, 2016, 36(Suppl 1): 72-77. DOI: 10.1111/liv.13001.
[6]	ROUSSELET MC, MICHALAK S, DUPRÉ F, et al. Sources of variability in histological scoring of chronic viral hepatitis[J]. Hepatology, 2005, 41(2): 257-264. DOI: 10.1002/hep.20535.
[7]	LU FM, DOU XG, ZHANG WH, et al. Clinical significance of serum HBV RNA measurement in chronic hepatitis B patients[J]. J Clin Hepatol, 2018, 34(5): 934-938. DOI: 10.3969/j.issn.1001-5256.2018.05.005. 鲁凤民, 窦晓光, 张文宏, 等. 慢性乙型肝炎患者血清HBV RNA检测的临床意义[J]. 临床肝胆病杂志, 2018, 34(5): 934-938. DOI: 10.3969/j.issn.1001-5256.2018.05.005.
[8]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[9]	ROTH GA, ABATE D, ABATE KH, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2018, 392(10159): 1736-1788. DOI: 10.1016/S0140-6736(18)32203-7.
[10]	GIERSCH K, ALLWEISS L, VOLZ T, et al. Serum HBV pgRNA as a clinical marker for cccDNA activity[J]. J Hepatol, 2017, 66(2): 460-462. DOI: 10.1016/j.jhep.2016.09.028.
[11]	TSUGE M, MURAKAMI E, IMAMURA M, et al. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients[J]. J Gastroenterol, 2013, 48(10): 1188-1204. DOI: 10.1007/s00535-012-0737-2.
[12]	MAK LY, CLOHERTY G, WONG DK, et al. HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy[J]. Hepatology, 2021, 73(6): 2167-2179. DOI: 10.1002/hep.31616.

Relative Articles

Supplements(0)

Cited By

Cited by

Periodical cited type(8)

1.	范雪莉，詹爱琴，安轶，田丽艳. 慢性乙型肝炎患者血清HBV RNA水平与核苷（酸）类似物治疗时间的关系. 临床肝胆病杂志. 2024(01): 58-63 . 本站查看
2.	曲紫瑶，孙建光，孔庆辉，王子宜. 慢性乙型肝炎患者血清乙型肝炎病毒RNA对核苷(酸)类似物治疗后HBeAg清除和血清转化的预测价值. 中国感染与化疗杂志. 2024(05): 521-529 .
3.	刘小花，蒋萍，连颖，余杨，王桂香，何幸，蒋华英，陈涛. HBeAg阳性及阴性乙肝患者血清HBV RNA与HBV DNA和转氨酶水平变化的相关性分析. 国际检验医学杂志. 2023(17): 2169-2172 .
4.	吴宝灵，徐龙，余海滨，徐贞秋，吴敏，张伟，范声春，李艳艳，李金明. 血清HBsAg、HBV RNA水平对慢性乙型肝炎患者核苷(酸)类药物治疗停药预测的价值. 实用临床医学. 2023(05): 1-4 .
5.	张福华，楚胜，李传俊，李先佳. 石蒜碱通过PI3K/AKT信号通路调节自噬抑制HBV诱发肝纤维化. 现代预防医学. 2022(04): 720-726 .
6.	胡鹏蕴，赵宏峰，杨小伟，史保宾. 新型促癌基因LSM11通过Wnt/β-catenin信号通路促进肝癌细胞增殖. 实用肝脏病杂志. 2022(05): 628-632 .
7.	林宝圆，陈志鸿. 慢性乙型肝炎患者血清HBV-DNA定量检测水平与肝功能指标的关系研究. 数理医药学杂志. 2022(11): 1632-1634 .
8.	李凤园，潘彤，王霞，张付华，龚华斐. 联检反应性鉴别非反应性献血者血浆标本乙型肝炎病毒感染情况的研究. 中国输血杂志. 2022(11): 1117-1120 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (721) PDF downloads(65)

Expression level of serum HBV RNA in HBeAg-positive chronic hepatitis B patients at different periods and its value of measurement

DOI: 10.3969/j.issn.1001-5256.2021.12.014